Orexo Interim Report Q1 2023
Focusing operations on Orexo´s strengths Q1 2023 highlights · Total net revenues of SEK 158.8 m (159.4) · EBITDA of SEK -41.1 m (2.8), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 20.9 m (32.2) · Net earnings of SEK -63.9 m (-23.6) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 140.3 m (139.1), in local currency USD 13.5 m (14.8), US Pharma EBIT of SEK 74.3 m (84.0) · Cash flow from operating activities of SEK -61.6 m (-61.6), cash and invested funds of SEK 278.9 m (437.8) · Earnings per share before and after dilution amounted